Form 8-K

8-K — Cytosorbents Corp

Accession: 0001104659-26-105901

Filed: 2026-09-08

Period: 2026-09-08

CIK: 0001175151

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Financial Statements and Exhibits

Documents

8-K — tm2624941d1_8k.htm (Primary)

EX-3.1 — EXHIBIT 3.1 (tm2624941d1_ex3-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2624941d1_8k.htm · Sequence: 1

false

--12-31

0001175151

2026-09-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 8, 2026

CytoSorbents Corporation

(Exact name of registrant as specified in

its charter)

Delaware

001-36792

98-0373793

(State or other

jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

305

College Road East

Princeton, New Jersey

08540

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including

area code (973) 329-8885

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b)

of the Securities Exchange Act of 1934:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CTSO

The NASDAQ Stock Market LLC

(Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change

in Fiscal Year.

On September 3, 2026, CytoSorbents

Corporation (the “Company”) announced that it would effect a one-for-twenty (1:20) reverse stock split (the “Reverse

Stock Split”) of its common stock, par value $0.001 per share (the “Common Stock”). The Reverse Stock Split was approved

by the shareholders of the Company at the 2026 Annual Meeting of Stockholders, held on August 13, 2026, with the final ratio to be determined

thereafter and within the shareholder-approved range by the Company’s board of directors (the “Board”).

The number of shares of the

Company’s Common Stock outstanding prior to the Reverse Stock Split as of September 3, 2026, was 63,022,020. On September 3, 2026,

the Company filed a certificate of amendment to amend the Company’s Second Amended and Restated Certificate of Incorporation (the

“Certificate of Amendment”) with the Secretary of State of the State of Delaware, with an effective date of September 8, 2026

(the “Effective Date”). The Reverse Stock Split became effective at 12:01 a.m. E.T. on September 8, 2026 (the “Effective

Time”).

Upon effectiveness of the

Reverse Stock Split, every twenty (20) shares of the Company’s issued and outstanding Common Stock immediately prior to the Effective

Time shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share. The Reverse

Stock Split resulted in a proportionate reduction in the number of shares of Common Stock issuable upon the exercise of the Company’s

outstanding options and warrants, with a corresponding adjustment to the exercise price per share applicable to each such option and warrant.

These adjustments occurred automatically upon effectiveness of the Reverse Stock Split. The Reverse Stock Split did not change the Company’s

total number of authorized shares of Common Stock.

No fractional shares were

issued as a result of the Reverse Stock Split. Shareholders who otherwise would be entitled to receive a fractional share in connection

with the Reverse Stock Split were entitled to have such fractional share rounded up to the nearest whole share.

Equiniti Trust Company, LLC,

is acting as exchange agent for the Reverse Stock Split and will notify shareholders of record regarding the Reverse Stock Split. Shareholders

who hold their shares in book-entry form or in “street name” (through a broker, bank or other holder of record) are not required

to take any action.

Commencing on September 8,

2026, trading of the Company’s Common Stock will continue on The Nasdaq Stock Market LLC on a split-adjusted basis. The new CUSIP

number for the Company’s Common Stock following the Reverse Stock Split is 23283X305.

The foregoing description

of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the

Certificate of Amendment, which is filed as Exhibit 3.1 to this report and incorporated herein by reference.

Item 9.01 Exhibits

(d) Exhibits

Exhibit

No.

Description

3.1

Certificate of Amendment of the Company, effective September 8, 2026

104

Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated: September 8, 2026

CYTOSORBENTS CORPORATION

By:

/s/ Dr. Phillip P. Chan

Name:

Dr. Phillip P. Chan

Title:

Chief Executive Officer

EX-3.1 — EXHIBIT 3.1

EX-3.1

Filename: tm2624941d1_ex3-1.htm · Sequence: 2

Exhibit 3.1

CERTIFICATE

OF AMENDMENT

THE

SECOND

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

CYTOSORBENTS

CORPORATION

CytoSorbents

Corporation, a corporation organized and existing by virtue of the General Corporation Law of the State of Delaware (the “Corporation”),

does hereby certify:

FIRST:

At the Effective Time (as defined below), each share of the Corporation’s common stock, $0.001 par value per share (the “Old

Common Stock”), either issued or outstanding or held by the Corporation as treasury stock, immediately prior to the Effective

Time, will be automatically reclassified and combined (without any further act) into a smaller number of shares such that each twenty

(20) shares of Old Common Stock issued and outstanding or held by the Corporation as treasury stock immediately prior to the Effective

Time is reclassified into one (1) share of Common Stock, $0.001 par value per share, of the Corporation (the “New Common Stock”),

without increasing or decreasing the amount of stated capital or paid-in surplus of the Corporation (the “Reverse Stock Split”).

The Board of Directors shall make provision for the issuance of that number of fractions of New Common Stock such that any fractional

share of a holder otherwise resulting from the Reverse Stock Split shall be rounded up to the next whole number of shares of New Common

Stock. Each stock certificate that, immediately prior to the Effective Time, represented shares of the Old Common Stock shall thereafter,

from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent the number

of shares of the New Common Stock into which such shares of Old Common Stock shall have been combined, subject to the treatment of fractional

shares as described above.”

SECOND:

The foregoing amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the

State of Delaware.

THIRD:

This Certificate of Amendment shall be effective as of 12:01 AM Eastern Time on September 8, 2026 (the “Effective Time”).

[SIGNATURE PAGE

FOLLOWS]

WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly executed in its corporate name and on its behalf

by its duly authorized officer this 3rd day of September, 2026.

CYTOSORBENTS

CORPORATION

By:

/s/

Dr. Phillip P. Chan

Name:

Dr. Phillip P. Chan

Title:

Chief Executive Officer

B-2

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Sep. 08, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 08, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-36792

Entity Registrant Name

CytoSorbents Corporation

Entity Central Index Key

0001175151

Entity Tax Identification Number

98-0373793

Entity Incorporation, State or Country Code

Entity Address, Address Line One

305

College Road East

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

973

Local Phone Number

329-8885

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CTSO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration